Details

Autor(en) / Beteiligte

• Smith, Ruben
• Capotosti, Francesca
• Schain, Martin
• Ohlsson, Tomas
• Vokali, Efthymia
• Molette, Jerome
• Touilloux, Tanja
• Hliva, Valerie
• Dimitrakopoulos, Ioannis K
• Puschmann, Andreas
• Jögi, Jonas
• Svenningsson, Per
• Andréasson, Mattias
• Sandiego, Christine
• Russell, David S
• Miranda-Azpiazu, Patricia
• Halldin, Christer
• Stomrud, Erik
• Hall, Sara
• Bratteby, Klas
• Tampio L'Estrade, Elina
• Luthi-Carter, Ruth
• Pfeifer, Andrea
• Kosco-Vilbois, Marie
• Streffer, Johannes
• Hansson, Oskar

Titel

The α-synuclein PET tracer [18F] ACI-12589 distinguishes multiple system atrophy from other neurodegenerative diseases

Ist Teil von

• Nature communications, 2023-10, Vol.14 (1), p.6750-6750, Article 6750

Ort / Verlag

England: Nature Publishing Group

Erscheinungsjahr

2023

Link zum Volltext

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• A positron emission tomography (PET) tracer detecting α-synuclein pathology will improve the diagnosis, and ultimately the treatment of α-synuclein-related diseases. Here we show that the PET ligand, [ F]ACI-12589, displays good in vitro affinity and specificity for pathological α-synuclein in tissues from patients with different α-synuclein-related disorders including Parkinson's disease (PD) and Multiple-System Atrophy (MSA) using autoradiography and radiobinding techniques. In the initial clinical evaluation we include 23 participants with α-synuclein related disorders, 11 with other neurodegenerative disorders and eight controls. In vivo [ F]ACI-12589 demonstrates clear binding in the cerebellar white matter and middle cerebellar peduncles of MSA patients, regions known to be highly affected by α-synuclein pathology, but shows limited binding in PD. The binding statistically separates MSA patients from healthy controls and subjects with other neurodegenerative disorders, including other synucleinopathies. Our results indicate that α-synuclein pathology in MSA can be identified using [ F]ACI-12589 PET imaging, potentially improving the diagnostic work-up of MSA and allowing for detection of drug target engagement in vivo of novel α-synuclein targeting therapies.